Analysts think AVXL stock price could increase by 500%
Aug 01, 2024, 6:25 AM
-11.47%
What does AVXL do
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company based in New York, develops therapeutics for neurodegenerative and neurodevelopmental disorders, utilizing precision medicine and genomic data to identify biomarkers. Its lead compound, ANAVEX 2-73, targets Alzheimer’s, Parkinson’s, and other CNS diseases, including Rett syndrome.
5 analysts think AVXL stock price will increase by 500.00%. The current median analyst target is $40.80 compared to a current stock price of $6.80. The lowest analysts target is $15.15 and the highest analyst target is $48.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.